{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:27:54Z","timestamp":1778570874038,"version":"3.51.4"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"7000","license":[{"start":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T00:00:00Z","timestamp":1091664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T00:00:00Z","timestamp":1091664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2004,8,5]]},"DOI":"10.1038\/nature02621","type":"journal-article","created":{"date-parts":[[2004,8,4]],"date-time":"2004-08-04T17:27:06Z","timestamp":1091640426000},"page":"631-639","source":"Crossref","is-referenced-by-count":2526,"title":["Pathways towards and away from Alzheimer's disease"],"prefix":"10.1038","volume":"430","author":[{"given":"Mark P.","family":"Mattson","sequence":"first","affiliation":[]}],"member":"297","reference":[{"key":"BFnature02621_CR1","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/S0197-4580(97)00065-1","volume":"18","author":"DW Dickson","year":"1997","unstructured":"Dickson, D. W. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol. Aging 18, S21\u2013S26 (1997)","journal-title":"Neurobiol. Aging"},{"key":"BFnature02621_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-7091-6467-9_11","volume":"53","author":"H Braak","year":"1998","unstructured":"Braak, H. & Braak, E. Evolution of neuronal changes in the course of Alzheimer's disease. J. Neural Transm. Suppl. 53, 127\u2013140 (1998)","journal-title":"J. Neural Transm. Suppl."},{"key":"BFnature02621_CR3","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1146\/annurev.pharmtox.43.100901.140248","volume":"43","author":"DJ Selkoe","year":"2003","unstructured":"Selkoe, D. J. & Schenk, D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43, 545\u2013584 (2003)","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"BFnature02621_CR4","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S0166-2236(96)01030-2","volume":"20","author":"J Hardy","year":"1997","unstructured":"Hardy, J. Amyloid, the presenilins and Alzheimer's disease. Trends Neurosci. 20, 154\u2013159 (1997)","journal-title":"Trends Neurosci."},{"key":"BFnature02621_CR5","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/375754a0","volume":"375","author":"R Sherrington","year":"1995","unstructured":"Sherrington, R. et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754\u2013760 (1995)","journal-title":"Nature"},{"key":"BFnature02621_CR6","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.7638622","volume":"269","author":"E Levy-Lahad","year":"1995","unstructured":"Levy-Lahad, E. et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973\u2013977 (1995)","journal-title":"Science"},{"key":"BFnature02621_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s100480050001","volume":"1","author":"AD Roses","year":"1997","unstructured":"Roses, A. D. A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease. Neurogenetics 1, 3\u201311 (1997)","journal-title":"Neurogenetics"},{"key":"BFnature02621_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0896-6273(01)00476-7","volume":"32","author":"RE Tanzi","year":"2001","unstructured":"Tanzi, R. E. & Bertram, L. New frontiers in Alzheimer's disease genetics. Neuron 32, 181\u2013184 (2001)","journal-title":"Neuron"},{"key":"BFnature02621_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev.neuro.26.043002.094919","volume":"26","author":"R Mayeux","year":"2003","unstructured":"Mayeux, R. Epidemiology of neurodegeneration. Annu. Rev. Neurosci. 26, 81\u2013104 (2003)","journal-title":"Annu. Rev. Neurosci."},{"key":"BFnature02621_CR10","doi-asserted-by":"publisher","first-page":"441","DOI":"10.7326\/0003-4819-139-5_Part_2-200309021-00012","volume":"139","author":"MP Mattson","year":"2003","unstructured":"Mattson, M. P. Gene-diet interactions in brain aging and neurodegenerative disorders. Ann. Intern. Med. 139, 441\u2013444 (2003)","journal-title":"Ann. Intern. Med."},{"key":"BFnature02621_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/7449","volume":"5","author":"D Young","year":"1999","unstructured":"Young, D. et al. Environmental enrichment inhibits spontaneous apoptosis, prevents seizures and is neuroprotective. Nature Med. 5, 448\u2013453 (1999)","journal-title":"Nature Med."},{"key":"BFnature02621_CR12","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1046\/j.1471-4159.2002.01085.x","volume":"82","author":"J Lee","year":"2002","unstructured":"Lee, J., Duan, W. & Mattson, M. P. Evidence that brain-derived neurotrophic factor is required for basal neurogenesis and mediates, in part, the enhancement of neurogenesis by dietary restriction in the hippocampus of adult mice. J. Neurochem. 82, 1367\u20131375 (2002)","journal-title":"J. Neurochem."},{"key":"BFnature02621_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0166-2236(02)02143-4","volume":"25","author":"CW Cotman","year":"2002","unstructured":"Cotman, C. W. & Berchtold, N. C. Exercise: a behavioral intervention to enhance brain health and plasticity. Trends Neurosci. 25, 295\u2013301 (2002)","journal-title":"Trends Neurosci."},{"key":"BFnature02621_CR14","doi-asserted-by":"publisher","first-page":"11193","DOI":"10.1073\/pnas.2135061100","volume":"100","author":"AI Bush","year":"2003","unstructured":"Bush, A. I., Masters, C. L. & Tanzi, R. E. Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc. Natl Acad. Sci. USA 100, 11193\u201311194 (2003)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR15","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/nm1295-1291","volume":"1","author":"C Haass","year":"1995","unstructured":"Haass, C. et al. The Swedish mutation causes early-onset Alzheimer's disease by beta-secretase cleavage within the secretory pathway. Nature Med. 1, 1291\u20131296 (1995)","journal-title":"Nature Med."},{"key":"BFnature02621_CR16","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner, D. et al. Secreted amyloid beta-protein similar to that in senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 APP mutations linked to familial Alzheimer's disease. Nature Med. 2, 864\u2013870 (1996)","journal-title":"Nature Med."},{"key":"BFnature02621_CR17","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1152\/physrev.1997.77.4.1081","volume":"77","author":"MP Mattson","year":"1997","unstructured":"Mattson, M. P. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol. Rev. 77, 1081\u20131132 (1997)","journal-title":"Physiol. Rev."},{"key":"BFnature02621_CR18","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/35050116","volume":"408","author":"D Morgan","year":"2000","unstructured":"Morgan, D. et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982\u2013985 (2000)","journal-title":"Nature"},{"key":"BFnature02621_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S1471-4914(01)02173-6","volume":"7","author":"DA Butterfield","year":"2001","unstructured":"Butterfield, D. A. et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7, 548\u2013554 (2001)","journal-title":"Trends Mol. Med."},{"key":"BFnature02621_CR20","doi-asserted-by":"publisher","first-page":"9866","DOI":"10.1073\/pnas.94.18.9866","volume":"94","author":"MA Smith","year":"1997","unstructured":"Smith, M. A. et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94, 9866\u20139868 (1997)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/jnr.10087","volume":"66","author":"JP Blass","year":"2001","unstructured":"Blass, J. P. Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J. Neurosci. Res. 66, 851\u2013856 (2001)","journal-title":"J. Neurosci. Res."},{"key":"BFnature02621_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0304-3940(99)00847-2","volume":"277","author":"JC Dodart","year":"1999","unstructured":"Dodart, J. C. et al. Early regional cerebral glucose hypometabolism in transgenic mice overexpressing the V717F beta-amyloid precursor protein. Neurosci. Lett. 277, 49\u201352 (1999)","journal-title":"Neurosci. Lett."},{"key":"BFnature02621_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0306-4522(02)00280-4","volume":"114","author":"M Buchner","year":"2002","unstructured":"Buchner, M., Huber, R., Sturchler-Pierrat, C., Staufenbiel, M. & Riepe, M. W. Impaired hypoxic tolerance and altered protein binding of NADH in presymptomatic APP23 transgenic mice. Neuroscience 114, 285\u2013289 (2002)","journal-title":"Neuroscience"},{"key":"BFnature02621_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00023210-200317010-00003","volume":"17","author":"GS Watson","year":"2003","unstructured":"Watson, G. S. & Craft, S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs 17, 27\u201345 (2003)","journal-title":"CNS Drugs"},{"key":"BFnature02621_CR25","doi-asserted-by":"publisher","first-page":"13623","DOI":"10.1016\/S0021-9258(17)36875-8","volume":"269","author":"D Gabuzda","year":"1994","unstructured":"Gabuzda, D., Busciglio, J., Chen, L. B., Matsudaira, P. & Yankner, B. A. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J. Biol. Chem. 269, 13623\u201313628 (1994)","journal-title":"J. Biol. Chem."},{"key":"BFnature02621_CR26","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1073\/pnas.90.7.2628","volume":"90","author":"K Saito","year":"1993","unstructured":"Saito, K. et al. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc. Natl Acad. Sci. USA 90, 2628\u20132632 (1993)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0143-4160(03)00128-3","volume":"34","author":"MP Mattson","year":"2003","unstructured":"Mattson, M. P. & Chan, S. L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34, 385\u2013397 (2003)","journal-title":"Cell Calcium"},{"key":"BFnature02621_CR28","doi-asserted-by":"publisher","first-page":"RC123","DOI":"10.1523\/JNEUROSCI.21-02-j0003.2001","volume":"21","author":"Y Le","year":"2001","unstructured":"Le, Y. et al. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci. 21, RC123 (2001)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR29","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrn960","volume":"3","author":"FM LaFerla","year":"2002","unstructured":"LaFerla, F. M. Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease. Nature Rev. Neurosci. 3, 862\u2013872 (2002)","journal-title":"Nature Rev. Neurosci."},{"key":"BFnature02621_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.neuroscience.2003.11.029","volume":"124","author":"Y Yang","year":"2004","unstructured":"Yang, Y. & Cook, D. G. Presenilin-1 deficiency impairs glutamate-evoked intracellular calcium responses in neurons. Neuroscience 124, 501\u2013506 (2004)","journal-title":"Neuroscience"},{"key":"BFnature02621_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1006\/nbdi.2000.0378","volume":"8","author":"A Eckert","year":"2001","unstructured":"Eckert, A. et al. Alzheimer's disease-like alterations in peripheral cells from presenilin-1 transgenic mice. Neurobiol. Dis. 8, 331\u2013342 (2001)","journal-title":"Neurobiol. Dis."},{"key":"BFnature02621_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nn0403-345","volume":"6","author":"L Puglielli","year":"2003","unstructured":"Puglielli, L., Tanzi, R. E. & Kovacs, D. M. Alzheimer's disease: the cholesterol connection. Nature Neurosci. 6, 345\u2013351 (2003)","journal-title":"Nature Neurosci."},{"key":"BFnature02621_CR33","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1001\/archneur.57.10.1439","volume":"57","author":"B Wolozin","year":"2000","unstructured":"Wolozin, B. et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439\u20131443 (2000)","journal-title":"Arch. Neurol."},{"key":"BFnature02621_CR34","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1073\/pnas.081620098","volume":"98","author":"K Fassbender","year":"2001","unstructured":"Fassbender, K. et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856\u20135861 (2001)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR35","first-page":"202","volume":"4","author":"S Kalmijn","year":"2000","unstructured":"Kalmijn, S. Fatty acid intake and the risk of dementia and cognitive decline: a review of clinical and epidemiological studies. J. Nutr. Health Aging 4, 202\u2013207 (2000)","journal-title":"J. Nutr. Health Aging"},{"key":"BFnature02621_CR36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1083\/jcb.200207113","volume":"160","author":"R Ehehalt","year":"2003","unstructured":"Ehehalt, R. et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 160, 113\u2013123 (2003)","journal-title":"J. Cell Biol."},{"key":"BFnature02621_CR37","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0305799101","volume":"101","author":"RG Cutler","year":"2004","unstructured":"Cutler, R. G. et al. Involvment of perturbed ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl Acad. Sci. USA 101, 2070\u20132075 (2004)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1017\/S1041610203008688","volume":"14","author":"M Farlow","year":"2002","unstructured":"Farlow, M. A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int. Psychogeriatr. 14, 93\u2013126 (2002)","journal-title":"Int. Psychogeriatr."},{"key":"BFnature02621_CR39","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","volume":"344","author":"MJ West","year":"1994","unstructured":"West, M. J. et al. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer's disease. Lancet 344, 769\u2013772 (1994)","journal-title":"Lancet"},{"key":"BFnature02621_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ana.410410106","volume":"41","author":"T Gomez-Isla","year":"1997","unstructured":"Gomez-Isla, T. et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41, 17\u201324 (1997)","journal-title":"Ann. Neurol."},{"key":"BFnature02621_CR41","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1126\/science.1091230","volume":"304","author":"JW Lustbader","year":"2004","unstructured":"Lustbader, J. W. et al. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304, 448\u2013452 (2004)","journal-title":"Science"},{"key":"BFnature02621_CR42","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/13550280290100969","volume":"8","author":"PL McGeer","year":"2002","unstructured":"McGeer, P. L. & McGeer, E. G. Local neuroinflammation and the progression of Alzheimer's disease. J. Neurovirol. 8, 529\u2013538 (2002)","journal-title":"J. Neurovirol."},{"key":"BFnature02621_CR43","doi-asserted-by":"publisher","first-page":"RC118","DOI":"10.1523\/JNEUROSCI.21-01-j0001.2001","volume":"21","author":"J Xu","year":"2001","unstructured":"Xu, J. et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J. Neurosci. 21, RC118 (2001)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR44","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177 (1999)","journal-title":"Nature"},{"key":"BFnature02621_CR45","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard, F. et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med. 6, 916\u2013919 (2000)","journal-title":"Nature Med."},{"key":"BFnature02621_CR46","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1523\/JNEUROSCI.22-06-02246.2002","volume":"22","author":"PT Jantzen","year":"2002","unstructured":"Jantzen, P. T. et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22, 2246\u20132254 (2002)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR47","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1002\/ana.410270502","volume":"27","author":"ST DeKosky","year":"1990","unstructured":"DeKosky, S. T. & Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol. 27, 457\u2013464 (1990)","journal-title":"Ann. Neurol."},{"key":"BFnature02621_CR48","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nn994","volume":"6","author":"KK Murai","year":"2003","unstructured":"Murai, K. K. et al. Control of hippocampal dendritic spine morphology through ephrin-A3\/EphA4 signaling. Nature Neurosci. 6, 153\u2013160 (2003)","journal-title":"Nature Neurosci."},{"key":"BFnature02621_CR49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1006\/exnr.1993.1202","volume":"124","author":"BJ Cummings","year":"1993","unstructured":"Cummings, B. J. et al. Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. Exp. Neurol. 124, 315\u2013325 (1993)","journal-title":"Exp. Neurol."},{"key":"BFnature02621_CR50","doi-asserted-by":"publisher","first-page":"9328","DOI":"10.1073\/pnas.92.20.9328","volume":"92","author":"SW Barger","year":"1995","unstructured":"Barger, S. W. et al. Tumor necrosis factors alpha and beta protect neurons against amyloid beta-peptide toxicity: evidence for involvement of a kappa B-binding factor and attenuation of peroxide and Ca2+ accumulation. Proc. Natl Acad. Sci. USA 92, 9328\u20139332 (1995)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR51","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.publhealth.24.100901.141015","volume":"24","author":"SK Pope","year":"2003","unstructured":"Pope, S. K., Shue, V. M. & Beck, C. Will a healthy lifestyle help prevent Alzheimer's disease? Annu. Rev. Public Health 24, 111\u2013132 (2003)","journal-title":"Annu. Rev. Public Health"},{"key":"BFnature02621_CR52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/archneur.61.1.82","volume":"61","author":"PP Zandi","year":"2004","unstructured":"Zandi, P. P. et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol. 61, 82\u201388 (2004)","journal-title":"Arch. Neurol."},{"key":"BFnature02621_CR53","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1212\/WNL.56.9.1188","volume":"56","author":"HX Wang","year":"2001","unstructured":"Wang, H. X. et al. Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology 56, 1188\u20131194 (2001)","journal-title":"Neurology"},{"key":"BFnature02621_CR54","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S1474-4422(02)00188-6","volume":"1","author":"L Dewachter","year":"2002","unstructured":"Dewachter, L. & Van Leuven, F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurol. 1, 409\u2013416 (2002)","journal-title":"Lancet Neurol."},{"key":"BFnature02621_CR55","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1021\/jm030247h","volume":"46","author":"V John","year":"2003","unstructured":"John, V. et al. Human beta-secretase (BACE) and BACE inhibitors. J. Med. Chem. 46, 4625\u20134630 (2003)","journal-title":"J. Med. Chem."},{"key":"BFnature02621_CR56","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1093\/hmg\/10.12.1317","volume":"10","author":"SL Roberds","year":"2001","unstructured":"Roberds, S. L. et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317\u20131324 (2001)","journal-title":"Hum. Mol. Genet."},{"key":"BFnature02621_CR57","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","volume":"60","author":"CW Ritchie","year":"2003","unstructured":"Ritchie, C. W. et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685\u20131691 (2003)","journal-title":"Arch. Neurol."},{"key":"BFnature02621_CR58","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk, D. et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173\u2013177 (1999)","journal-title":"Nature"},{"key":"BFnature02621_CR59","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1038\/nm790","volume":"8","author":"J McLaurin","year":"2002","unstructured":"McLaurin, J. et al. Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis. Nature Med. 8, 1263\u20131269 (2002)","journal-title":"Nature Med."},{"key":"BFnature02621_CR60","doi-asserted-by":"publisher","first-page":"6331","DOI":"10.1523\/JNEUROSCI.22-15-06331.2002","volume":"22","author":"LA Kotilinek","year":"2002","unstructured":"Kotilinek, L. A. et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 22, 6331\u20136335 (2002)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR61","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","volume":"38","author":"C Hock","year":"2003","unstructured":"Hock, C. et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547\u2013554 (2003)","journal-title":"Neuron"},{"key":"BFnature02621_CR62","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2174\/1389450033490902","volume":"4","author":"JJ Hoozemans","year":"2003","unstructured":"Hoozemans, J. J. et al. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Curr. Drug Targets 4, 461\u2013468 (2003)","journal-title":"Curr. Drug Targets"},{"key":"BFnature02621_CR63","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1001\/jama.288.17.2170","volume":"288","author":"SM Resnick","year":"2002","unstructured":"Resnick, S. M. & Henderson, V. W. Hormone therapy and risk of Alzheimer disease. J. Am. Med. Assoc. 288, 2170\u20132172 (2002)","journal-title":"J. Am. Med. Assoc."},{"key":"BFnature02621_CR64","doi-asserted-by":"publisher","first-page":"27765","DOI":"10.1074\/jbc.273.43.27765","volume":"273","author":"JD Buxbaum","year":"1998","unstructured":"Buxbaum, J. D. et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 27765\u201327767 (1998)","journal-title":"J. Biol. Chem."},{"key":"BFnature02621_CR65","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0006-291X(02)02999-6","volume":"301","author":"M Asai","year":"2003","unstructured":"Asai, M. et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem. Biophys. Res. Commun. 301, 231\u2013235 (2003)","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnature02621_CR66","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1073\/pnas.072033799","volume":"99","author":"MA Leissring","year":"2002","unstructured":"Leissring, M. A. et al. A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc. Natl Acad. Sci. USA 99, 4697\u20134702 (2002)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR67","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/74656","volume":"6","author":"DC Lu","year":"2000","unstructured":"Lu, D. C. et al. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor. Nature Med. 6, 397\u2013404 (2000)","journal-title":"Nature Med."},{"key":"BFnature02621_CR68","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/35024009","volume":"407","author":"G Yu","year":"2000","unstructured":"Yu, G. et al. Nicastrin modulates presenilin-mediated notch\/glp-1 signal transduction and betaAPP processing. Nature 407, 48\u201354 (2000)","journal-title":"Nature"},{"key":"BFnature02621_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S1534-5807(02)00189-2","volume":"3","author":"R Francis","year":"2002","unstructured":"Francis, R. et al. aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation. Dev. Cell 3, 85\u201397 (2002)","journal-title":"Dev. Cell"},{"key":"BFnature02621_CR70","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/nature01506","volume":"422","author":"N Takasugi","year":"2003","unstructured":"Takasugi, N. et al. The role of presenilin cofactors in the gamma-secretase complex. Nature 422, 438\u2013441 (2003)","journal-title":"Nature"},{"key":"BFnature02621_CR71","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0092-8674(00)80244-5","volume":"89","author":"J Shen","year":"1997","unstructured":"Shen, J. et al. Skeletal and CNS defects in Presenilin-1-deficient mice. Cell 89, 629\u2013639 (1997)","journal-title":"Cell"},{"key":"BFnature02621_CR72","doi-asserted-by":"publisher","first-page":"9785","DOI":"10.1523\/JNEUROSCI.22-22-09785.2002","volume":"22","author":"O Lazarov","year":"2002","unstructured":"Lazarov, O., Lee, M., Peterson, D. A. & Sisodia, S. S. Evidence that synaptically released beta-amyloid accumulates as extracellular deposits in the hippocampus of transgenic mice. J. Neurosci. 22, 9785\u20139793 (2002)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR73","doi-asserted-by":"publisher","first-page":"40288","DOI":"10.1074\/jbc.C100447200","volume":"276","author":"WT Kimberly","year":"2001","unstructured":"Kimberly, W. T. et al. The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J. Biol. Chem. 276, 40288\u201340292 (2001)","journal-title":"J. Biol. Chem."},{"key":"BFnature02621_CR74","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1126\/science.2218531","volume":"250","author":"BA Yankner","year":"1990","unstructured":"Yankner, B. A. et al. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 250, 279\u2013282 (1990)","journal-title":"Science"},{"key":"BFnature02621_CR75","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.1073\/pnas.95.11.6448","volume":"95","author":"MP Lambert","year":"1998","unstructured":"Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Abeta1\u201342 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448\u20136453 (1998)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR76","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1126\/science.1079469","volume":"300","author":"R Kayed","year":"2003","unstructured":"Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486\u2013489 (2003)","journal-title":"Science"},{"key":"BFnature02621_CR77","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/6374","volume":"2","author":"PF Chapman","year":"1999","unstructured":"Chapman, P. F. et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neurosci. 2, 271\u2013276 (1999)","journal-title":"Nature Neurosci."},{"key":"BFnature02621_CR78","doi-asserted-by":"publisher","first-page":"14675","DOI":"10.1073\/pnas.261562998","volume":"98","author":"M Koistinaho","year":"2001","unstructured":"Koistinaho, M. et al. Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta-amyloid deposits but do not form plaques. Proc. Natl Acad. Sci. USA 98, 14675\u201314680 (2001)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR79","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S0896-6273(03)00124-7","volume":"37","author":"F Kamenetz","year":"2003","unstructured":"Kamenetz, F. et al. APP processing and synaptic function. Neuron 37, 925\u2013937 (2003)","journal-title":"Neuron"},{"key":"BFnature02621_CR80","doi-asserted-by":"publisher","first-page":"10417","DOI":"10.1073\/pnas.1834302100","volume":"100","author":"Y Gong","year":"2003","unstructured":"Gong, Y. et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl Acad. Sci. USA 100, 10417\u201310422 (2003)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature02621_CR81","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0166-2236(00)01749-5","volume":"24","author":"WL Klein","year":"2001","unstructured":"Klein, W. L., Krafft, G. A. & Finch, C. E. Targeting small A\u03b2 oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219\u2013224 (2001)","journal-title":"Trends Neurosci."},{"key":"BFnature02621_CR82","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.1523\/JNEUROSCI.16-21-06732.1996","volume":"16","author":"ML Oster-Granite","year":"1996","unstructured":"Oster-Granite, M. L. et al. Age-dependent neuronal and synaptic degeneration in mice transgenic for the C terminus of the amyloid precursor protein. J. Neurosci. 16, 6732\u20136741 (1996)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR83","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","volume":"39","author":"S Oddo","year":"2003","unstructured":"Oddo, S. et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409\u2013421 (2003)","journal-title":"Neuron"},{"key":"BFnature02621_CR84","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","volume":"20","author":"L Mucke","year":"2000","unstructured":"Mucke, L. et al. High-level neuronal expression of abeta 1\u201342 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050\u20134058 (2000)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR85","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1385\/NMM:2:2:167","volume":"2","author":"SL Chan","year":"2002","unstructured":"Chan, S. L., Furukawa, K. & Mattson, M. P. Presenilins APP in neuritic and synaptic plasticity: implications for the pathogenesis of Alzheimer's disease. Neuromolecular Med. 2, 167\u2013196 (2002)","journal-title":"Neuromolecular Med."},{"key":"BFnature02621_CR86","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00117-003-0925-4","volume":"43","author":"R Stahl","year":"2003","unstructured":"Stahl, R. et al. Assessment of axonal degeneration on Alzheimer's disease with diffusion tensor MRI. Radiologe 43, 566\u2013575 (2003)","journal-title":"Radiologe"},{"key":"BFnature02621_CR87","doi-asserted-by":"publisher","first-page":"9629","DOI":"10.1523\/JNEUROSCI.18-23-09629.1998","volume":"18","author":"JD Buxbaum","year":"1998","unstructured":"Buxbaum, J. D. et al. Alzheimer amyloid protein precursor in the rat hippocampus: transport and processing through the perforant path. J. Neurosci. 18, 9629\u20139637 (1998)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR88","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.neurobiolaging.2003.04.007","volume":"24","author":"EM Mandelkow","year":"2003","unstructured":"Mandelkow, E. M. et al. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24, 1079\u20131085 (2003)","journal-title":"Neurobiol. Aging"},{"key":"BFnature02621_CR89","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","volume":"24","author":"VM Lee","year":"2001","unstructured":"Lee, V. M., Goedert, M. & Trojanowski, J. Q. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24, 1121\u20131159 (2001)","journal-title":"Annu. Rev. Neurosci."},{"key":"BFnature02621_CR90","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1212\/WNL.56.1.127","volume":"56","author":"E Masliah","year":"2001","unstructured":"Masliah, E. et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 56, 127\u2013129 (2001)","journal-title":"Neurology"},{"key":"BFnature02621_CR91","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tins.2003.10.012","volume":"27","author":"PJ Yao","year":"2004","unstructured":"Yao, P. J. Synaptic frailty and clathrin-mediated synaptic vesicle trafficking in Alzheimer's disease. Trends Neurosci. 27, 24\u201329 (2004)","journal-title":"Trends Neurosci."},{"key":"BFnature02621_CR92","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/35037739","volume":"407","author":"J Yuan","year":"2000","unstructured":"Yuan, J. & Yankner, B. A. Apoptosis in the nervous system. Nature 407, 802\u2013809 (2000)","journal-title":"Nature"},{"key":"BFnature02621_CR93","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/35040009","volume":"1","author":"MP Mattson","year":"2000","unstructured":"Mattson, M. P. Apoptosis in neurodegenerative disorders. Nature Rev. Mol. Cell Biol. 1, 120\u2013129 (2000)","journal-title":"Nature Rev. Mol. Cell Biol."},{"key":"BFnature02621_CR94","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0006-2952(03)00534-3","volume":"66","author":"A Eckert","year":"2003","unstructured":"Eckert, A. et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem. Pharmacol. 66, 1627\u20131634 (2003)","journal-title":"Biochem. Pharmacol."},{"key":"BFnature02621_CR95","doi-asserted-by":"publisher","first-page":"6914","DOI":"10.1523\/JNEUROSCI.23-17-06914.2003","volume":"23","author":"DL McPhie","year":"2003","unstructured":"McPhie, D. L. et al. DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3. J. Neurosci. 23, 6914\u20136927 (2003)","journal-title":"J. Neurosci."},{"key":"BFnature02621_CR96","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/35012636","volume":"405","author":"MS Lee","year":"2000","unstructured":"Lee, M. S. et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360\u2013364 (2000)","journal-title":"Nature"},{"key":"BFnature02621_CR97","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S0896-6273(04)00017-0","volume":"41","author":"II Kruman","year":"2004","unstructured":"Kruman, I. I. et al. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 41, 549\u2013561 (2004)","journal-title":"Neuron"},{"key":"BFnature02621_CR98","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1126\/science.279.5348.242","volume":"279","author":"FW Van Leeuwen","year":"1998","unstructured":"Van Leeuwen, F. W. et al. Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279, 242\u2013247 (1998)","journal-title":"Science"},{"key":"BFnature02621_CR99","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.molcel.2003.08.005","volume":"12","author":"S Song","year":"2003","unstructured":"Song, S. et al. Essential role of E2\u201325K\/Hip-2 in mediating amyloid-beta neurotoxicity. Mol. Cell 12, 553\u2013563 (2003)","journal-title":"Mol. Cell"},{"key":"BFnature02621_CR100","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1523\/JNEUROSCI.22-02-00404.2002","volume":"22","author":"WA Pedersen","year":"2002","unstructured":"Pedersen, W. A., Wan, R., Zhang, P. & Mattson, M. P. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J. Neurosci. 22, 404\u2013412 (2002)","journal-title":"J. Neurosci."}],"updated-by":[{"DOI":"10.1038\/nature02940","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2004,9,2]],"date-time":"2004-09-02T00:00:00Z","timestamp":1094083200000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature02621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature02621","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature02621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,14]],"date-time":"2024-01-14T02:39:30Z","timestamp":1705199970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature02621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8,5]]},"references-count":100,"journal-issue":{"issue":"7000","published-print":{"date-parts":[[2004,8,5]]}},"alternative-id":["BFnature02621"],"URL":"https:\/\/doi.org\/10.1038\/nature02621","relation":{"erratum":[{"id-type":"doi","id":"10.1038\/nature02940","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,8,5]]}}}